Related references
Note: Only part of the references are listed.Manufacturer Revenue on Inhalers After Expiration of Primary Patents, 2000-2021
William B. Feldman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2023)
Clinical development times for innovative drugs
Dean G. Brown et al.
NATURE REVIEWS DRUG DISCOVERY (2022)
Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia
Jefferson Antonio Buendia et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD
Dave Singh et al.
EUROPEAN RESPIRATORY JOURNAL (2022)
Machine Learning for Solar Resource Assessment Using Satellite Images
Luis Eduardo Ordonez Palacios et al.
ENERGIES (2022)
Thermal-Airflow Coupling in Hourly Energy Simulation of a Building with Natural Stack Ventilation
Piotr Michalak
ENERGIES (2022)
Reduction of the Risk of Inaccurate Prediction of Electricity Generation from PV Farms Using Machine Learning
Maria Krechowicz et al.
ENERGIES (2022)
Discovery of Clinical Candidate CHF-6366: A Novel Super-soft Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases
Laura Carzaniga et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
An Enhancement of the Solar Panel Efficiency: A Comprehensive Review
R. Parthiban et al.
FRONTIERS IN ENERGY RESEARCH (2022)
Machine Learning Analysis on the Performance of Dye-Sensitized Solar Cell-Thermoelectric Generator Hybrid System
Zoltan Varga et al.
ENERGIES (2022)
Type 2 inflammation in asthma and other airway diseases
Jorge Maspero et al.
ERJ OPEN RESEARCH (2022)
Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies
Luigino Calzetta et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2021)
Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact
Mairi MacLeod et al.
RESPIROLOGY (2021)
A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
Gary T. Ferguson et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2021)
Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life
John R. Hurst et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018
Olivier J. Wouters et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD)
Luigino Calzetta et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
A randomized, controlled, repeat-dose study of batefenterol/fluticasone furoate compared with placebo in the treatment of COPD
Courtney Crim et al.
BMC PULMONARY MEDICINE (2020)
Bayesian alternatives to null hypothesis significance testing in biomedical research: a non-technical introduction to Bayesian inference with JASP
Riko Kelter
BMC MEDICAL RESEARCH METHODOLOGY (2020)
Role of Type2 Inflammatory Biomarkers in Chronic Obstructive Pulmonary Disease
Keiji Oishi et al.
JOURNAL OF CLINICAL MEDICINE (2020)
A dose-ranging study of the inhaled dual phosphodiesterase 3 and 4 inhibitor ensifentrine in COPD
Dave Singh et al.
RESPIRATORY RESEARCH (2020)
Introduction to precision medicine in COPD
Janice M. Leung et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report
Vanessa M. McDonald et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD
Mario Cazzola et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2019)
Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients
Luigino Calzetta et al.
ADVANCES IN THERAPY (2019)
Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma
Leif Bjermer et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2019)
At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease
Fernando J. Martinez et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy
Luigino Calzetta et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Correlations between FEV1 and patient-reported outcomes: A pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease
James F. Donohue et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2018)
Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how
Luigino Calzetta et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2018)
The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
Dave Singh et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
What is early COPD and why is it important?
Joan B. Soriano et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Ensifentrine (RPL554): an inhaled bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease
Mario Cazzola et al.
PHARMACEUTICAL PATENT ANALYST (2018)
Understanding the impact of symptoms on the burden of COPD
Marc Miravitlles et al.
RESPIRATORY RESEARCH (2017)
Clinical Trial Risk in Chronic Obstructive Pulmonary Disease: The Effects of Drug Class and Inclusion Criteria
Jeffrey T. Y. Tam et al.
RESPIRATION (2016)
Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility
R. Venkatasamy et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Treatable traits: toward precision medicine of chronic airway diseases
Alvar Agusti et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease
Mario Cazzola et al.
EXPERT OPINION ON DRUG DISCOVERY (2016)
Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3)
Donald A. Mahler et al.
RESPIRATORY MEDICINE (2016)
Matched-Comparative Modeling of Normal and Diseased Human Airway Responses Using a Microengineered Breathing Lung Chip
Kambez H. Benam et al.
CELL SYSTEMS (2016)
Efficacy and Safety of Twice-Daily Glycopyrrolate Versus Placebo in Patients With COPD: The GEM2 Study
Edward Kerwin et al.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION (2016)
Relationship Between FEV1 and Patient-Reported Outcomes Changes: Results of a Meta-Analysis of Randomized Trials in Stable COPD
Christine de la Loge et al.
CHRONIC OBSTRUCTIVE PULMONARY DISEASES-JOURNAL OF THE COPD FOUNDATION (2016)
Probabilistic machine learning and artificial intelligence
Zoubin Ghahramani
NATURE (2015)
Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways
Luigino Calzetta et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2015)
Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
Domenico Spina
EUROPEAN CLINICAL RESPIRATORY JOURNAL (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Eosinophilic inflammation in COPD: prevalence and clinical characteristics
Dave Singh et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
A new class of bronchodilator improves Lung function in COPD: a trial with GSK961081
Pascal L. M. L. Wielders et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
The MABA approach: a new option to improve bronchodilator therapy
Mario Cazzola et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Dual PDE 3/4 inhibition: a novel approach to airway disease?
Jadwiga A. Wedzicha
LANCET RESPIRATORY MEDICINE (2013)
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
Lui G. Franciosi et al.
LANCET RESPIRATORY MEDICINE (2013)
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone
Luigino Calzetta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
A new Bayesian approach to quantile autoregressive time series model estimation and forecasting
Yuzhi Cai et al.
JOURNAL OF TIME SERIES ANALYSIS (2012)
Pharmacology and Therapeutics of Bronchodilators
Mario Cazzola et al.
PHARMACOLOGICAL REVIEWS (2012)
Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma
Ashley Woodcock et al.
RESPIRATORY RESEARCH (2011)
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
Victoria Boswell-Smith et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Roflumilast -: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease:: a randomised controlled trial
KF Rabe et al.
LANCET (2005)
COPD: is there light at the end of the tunnel?
PJ Barnes
CURRENT OPINION IN PHARMACOLOGY (2004)
Effect of interpretive bias on research evidence
TJ Kaptchuk
BRITISH MEDICAL JOURNAL (2003)
Quantile regression: applications and current research areas
KM Yu et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES D-THE STATISTICIAN (2003)
Share Paper
